The Camcevi China approval 2026 gives men with advanced prostate cancer in China a six-month hormone injection that is supplied ready to use. On 12 October 2026, Foresee Pharmaceuticals announced that China’s National Medical Products Administration (NMPA) had approved Camcevi 42 mg, a subcutaneous formulation of leuprolide mesylate, for adults with advanced prostate cancer. Changchun GeneScience Pharmaceutical, Foresee’s licensing partner, will market it in China.
This is a Chinese regulatory decision. It is not a new US approval, and the announcement contains no new clinical trial results. Below is what was approved, what is known about the drug, and what remains unclear.
Key takeaways
- The NMPA approved Camcevi 42 mg for adults with advanced prostate cancer.
- Camcevi is a ready-to-use leuprolide mesylate injection given under the skin every six months.
- Changchun GeneScience Pharmaceutical will commercialise the drug in China.
- A separate application for premenopausal breast cancer is under review, according to reports.
- The exact approval date and the price in China were not given in the information we reviewed.
What the Camcevi China approval 2026 covers
Camcevi is leuprolide mesylate, a GnRH agonist. Drugs in this class lower testosterone, which fuels many prostate cancers, and are a mainstay of androgen deprivation therapy. The National Cancer Institute explains that hormone therapy is used when prostate cancer has spread or returned.
Foresee’s version is supplied in a pre-filled syringe, so it does not need to be mixed before use, and one injection lasts six months. Reports say this cuts clinic visits from monthly or quarterly to twice a year. Whether that matters to patients depends on how treatment is delivered in China, which the announcement does not discuss.
Why the Camcevi China approval 2026 matters for dosing
Men on androgen deprivation therapy often stay on it for years, so the injection schedule shapes daily life. Fewer visits can mean less travel, fewer missed doses and lower demand on busy oncology clinics. A ready-to-use syringe also removes a preparation step that can go wrong in a hurry. These are practical benefits; they do not by themselves change how long patients live. Anyone considering a switch between formulations should talk to their oncologist, because the right product depends on the stage of disease and other treatment.
Who will sell it in China
Changchun GeneScience Pharmaceutical, a subsidiary of Changchun High-Tech Industry (Group), holds the exclusive licence for China. Reports on the licensing agreement, signed in November 2020, describe an $8 million upfront payment, up to about $123.85 million in milestones and tiered royalties. We could not confirm those terms in the company’s own text, so treat them as reported. Foresee chairman and chief executive Ben Chien said the approval should contribute significantly to the growth of the company’s global Camcevi franchise.
Evidence behind the Camcevi China approval 2026
The approval in China is not backed by new data in this announcement. Earlier reporting on the US Phase 3 study, which led to the US approval, described 137 patients and said 97% reached testosterone levels at or below 50 ng/dL, with a mean of 17.6 ng/dL by day 28 and castrate-level suppression maintained from week 4 to week 48. The trial reports we saw were inconsistent on some details, so we cite these figures with caution. They measure hormone levels, not survival.
The most common side effects listed for the product (10% or more of patients) include hot flushes, high blood pressure, injection-site reactions, upper respiratory infections, musculoskeletal pain, fatigue and limb pain. Allergic reactions are possible in people who are hypersensitive to GnRH drugs.
How the Camcevi China approval 2026 fits earlier approvals
The US Food and Drug Administration approved Camcevi 42 mg in May 2021, and it has been sold in the US since 2022 through Accord BioPharma. The company also says it is approved in the European Union; we have not verified that. China adds a large market where prostate cancer is increasingly diagnosed. For another recent China regulatory story, see our report on Velsipity local manufacturing in China getting priority review.
A national approval is only the first step. Before patients can receive the drug, the licensee must set a price, secure hospital listings and, ideally, win a place on the national reimbursement list. Those steps often take many months, and the announcement gives no timetable for any of them.
The breast cancer application
Reports say Changchun GeneScience submitted a supplemental application in May 2026 for use in premenopausal breast cancer, which the NMPA has accepted for review. Review does not mean approval, and nothing in the announcement shows how the review will end. The product is also being positioned for central precocious puberty, according to the same reports.
Our assessment of the Camcevi China approval 2026
In our assessment, the Camcevi China approval 2026 is mainly a commercial and convenience story. Leuprolide is an old, well-understood class, and the new element is the delivery format and the length of dosing. That can help patients and clinics, yet it does not show better cancer outcomes than existing hormone injections. The commercial result will depend on pricing, reimbursement and competition from other long-acting GnRH products in China. For more regulatory coverage, browse our pharmaceutical reports, or see our report on early results for a prostate surgery nerve-repair device.
What to watch next after the Camcevi China approval 2026
- The China launch date, price and reimbursement.
- The NMPA decision on the breast cancer application.
- Any local data in Chinese patients.
- Further regulatory filings in other Asian markets.
Frequently asked questions
What is the Camcevi China approval 2026?
China’s NMPA approved Camcevi 42 mg, a six-month leuprolide mesylate injection, for adults with advanced prostate cancer.
Is the Camcevi China approval 2026 an FDA approval?
No. The FDA approved Camcevi 42 mg in 2021; the Chinese decision is separate.
Who will market Camcevi in China?
Changchun GeneScience Pharmaceutical, Foresee’s exclusive licensee for China.
How often is Camcevi given after the China approval 2026?
One subcutaneous injection every six months, supplied in a pre-filled syringe.
Is it approved for breast cancer?
No. An application for premenopausal breast cancer is under review.
How we reported this: we relied on Foresee Pharmaceuticals’ 12 October 2026 announcement as summarised in trade reporting and on earlier US approval and trial coverage. We could not open the full release. Last updated: 14 October 2026. This article is news reporting and not medical advice.